Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on Zanubrutinib PK in Healthy Adults
NCT04163523Phase 1Completed
- Sponsor
- BeiGene
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zanubrutinib in B cell malignancies (3 arms), sponsored by BeiGene. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to 24 Hours, Area Under the Concentration-Time Curve from Time Zero to Infinity at 2 months and 3 more. Started May 2016; status: completed.
02
Drugs
zanubrutinib
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT04163523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163523.